Menu
← Oncology Approval Tracker
FDA DECISION ·
Udenyca Onbody
pegfilgrastim-cbqv · Coherus BioSciences
Open LinkedIn brief ↓1 min read · estimated
APPROVED USE
What FDA approved
An on-body injector presentation for Udenyca to lower infection risk from febrile neutropenia in qualifying patients with nonmyeloid malignancies receiving myelosuppressive anticancer therapy.
LAMPGEN ANALYSIS
Why it matters
The new delivery presentation can separate device placement from drug administration.
What research teams should watch
Train staff and patients on correct placement, delivery confirmation and management of device failure.
PRIMARY RECORDS